Acorda to buy Civitas Therapeutics for $525 million

Acorda Therapeutics says it will buy fellow drug maker Civitas Therapeutics for $525 million in cash, which will give Acorda rights to Civitas’ treatment candidate for episodes of Parkinson’s disease.